The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

21 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
3
Discovery of novel DNA methyltransferase 3A inhibitors via structure-based virtual screening and biological assays.EBI
University of Science and Technology of China
4
Design and synthesis of new non nucleoside inhibitors of DNMT3A.EBI
Unit£
3
Discovery of a Dual PRMT5-PRMT7 Inhibitor.EBI
University of Toronto
15
Targeting DNA methylation with small molecules: what's next?EBI
Cnrs-Pierre Fabre
13
Identifying novel selective non-nucleoside DNA methyltransferase 1 inhibitors through docking-based virtual screening.EBI
Chinese Academy of Sciences
6
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.EBI
TBA
19
Design and Synthesis of Novel Deazapurine DNMT 1 Inhibitors with In Vivo Efficacy in DLBCL.EBI
Sichuan University
28
A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins.EBI
University of Toronto
31
Inhibitors targeting the PWWP domain-containing proteins.EBI
Central China Normal University
2
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.EBI
Daiichi Sankyo Co., Ltd
14
Structural Investigations of Phthalazinone Derivatives as Allosteric Inhibitors of Human DNA Methyltransferase 3A.EBI
University of California
36
Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity.EBI
Shandong University
20
Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets.EBI
University of Palermo
9
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.EBI
Southern Medical University
2
A novel class of selective non-nucleoside inhibitors of human DNA methyltransferase 3A.EBI
University of California
4
Novel anticancer drug curaxin CBL0137 impairs DNA methylation by eukaryotic DNA methyltransferase Dnmt3a.EBI
M. V. Lomonosov Moscow State University
35
High-Affinity Alkynyl Bisubstrate Inhibitors of Nicotinamide EBI
Biokin
19
Identification of novel quinazoline derivatives as potent antiplasmodial agents.EBI
University of Lille
10
Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.EBI
National University of Singapore
11
Rational Design of Bisubstrate-Type Analogues as Inhibitors of DNA Methyltransferases in Cancer Cells.EBI
Cnrs-Pierre Fabre Usr3388
19
Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors.BDB
The Scripps Research Institute